CENTRAL TRUST Co decreased its position in shares of HCA Healthcare Inc (NYSE:HCA) by 19.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 944 shares of the company’s stock after selling 226 shares during the period. CENTRAL TRUST Co’s holdings in HCA Healthcare were worth $123,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. Standard Life Aberdeen plc grew its holdings in shares of HCA Healthcare by 8.3% during the 3rd quarter. Standard Life Aberdeen plc now owns 113,267 shares of the company’s stock worth $15,759,000 after acquiring an additional 8,677 shares during the period. LPL Financial LLC grew its stake in shares of HCA Healthcare by 20.5% in the 3rd quarter. LPL Financial LLC now owns 9,753 shares of the company’s stock worth $1,357,000 after buying an additional 1,661 shares during the last quarter. Macquarie Group Ltd. grew its stake in shares of HCA Healthcare by 11.6% in the 3rd quarter. Macquarie Group Ltd. now owns 11,308 shares of the company’s stock worth $1,574,000 after buying an additional 1,177 shares during the last quarter. Glenmede Trust Co. NA lifted its position in HCA Healthcare by 164.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,274 shares of the company’s stock valued at $176,000 after acquiring an additional 793 shares in the last quarter. Finally, Rehmann Capital Advisory Group lifted its position in HCA Healthcare by 12,665.9% in the 3rd quarter. Rehmann Capital Advisory Group now owns 21,702 shares of the company’s stock valued at $156,000 after acquiring an additional 21,532 shares in the last quarter. Hedge funds and other institutional investors own 71.29% of the company’s stock.
In other HCA Healthcare news, insider Jon M. Foster sold 44,281 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $122.28, for a total value of $5,414,680.68. Following the completion of the sale, the insider now owns 96,052 shares in the company, valued at approximately $11,745,238.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.70% of the company’s stock.
HCA Healthcare stock traded down $2.87 during trading on Friday, reaching $123.84. The company had a trading volume of 1,743,308 shares, compared to its average volume of 1,938,884. HCA Healthcare Inc has a 52 week low of $101.30 and a 52 week high of $147.42. The stock has a market cap of $43.37 billion, a P/E ratio of 12.68, a P/E/G ratio of 1.03 and a beta of 0.75.
HCA Healthcare (NYSE:HCA) last announced its earnings results on Tuesday, April 30th. The company reported $2.97 EPS for the quarter, topping the Zacks’ consensus estimate of $2.31 by $0.66. HCA Healthcare had a negative return on equity of 112.65% and a net margin of 7.71%. The company had revenue of $12.52 billion for the quarter, compared to analysts’ expectations of $12.34 billion. During the same period last year, the firm earned $3.18 EPS. HCA Healthcare’s revenue for the quarter was up 9.6% compared to the same quarter last year. As a group, equities research analysts anticipate that HCA Healthcare Inc will post 10.38 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 3rd will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, May 31st. This represents a $1.60 dividend on an annualized basis and a yield of 1.29%. HCA Healthcare’s payout ratio is presently 16.38%.
Several equities analysts recently issued reports on the company. Zacks Investment Research raised HCA Healthcare from a “hold” rating to a “buy” rating and set a $139.00 price objective on the stock in a research report on Friday, May 3rd. UBS Group upped their price objective on HCA Healthcare from $164.00 to $172.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Deutsche Bank upped their price objective on HCA Healthcare from $160.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Raymond James raised HCA Healthcare from a “market perform” rating to an “outperform” rating and increased their price target for the company from $115.00 to $135.00 in a report on Tuesday, April 23rd. Finally, Jefferies Financial Group set a $158.00 price target on HCA Healthcare and gave the company a “buy” rating in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company. HCA Healthcare has an average rating of “Buy” and an average price target of $149.41.
COPYRIGHT VIOLATION NOTICE: “CENTRAL TRUST Co Has $123,000 Holdings in HCA Healthcare Inc (HCA)” was reported by Sundance Herald and is owned by of Sundance Herald. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://sundanceherald.com/2019/05/24/hca-healthcare-inc-hca-position-cut-by-central-trust-co.html.
HCA Healthcare Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Read More: What is a CD ladder?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.